Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Guangzhou Welman Pharmaceutical Wins Patent Authorization Lawsuit

This article was originally published in PharmAsia News

Executive Summary

The antibiotic piperacillin-shubatanna patent authorization lawsuit between Shanghai Asia Pioneer Pharmaceutical and Guangzhou Welman Pharmaceutical recently came to a close. The China International Economic and Trade Arbitration Commission ruled that Asia Pioneer has infringed on Welman's patent and needs to pay RMB 4.7 million ($687,838) compensation. In 2005, Welman transferred its piperacillin-shubatanna patent to Asia Pioneer at RMB 80 million, the highest patent transfer fee in China's pharmaceutical industry to date. However, Welman withdrew its patent from Asia Pioneer two years later for not paying the patent royalty, but the latter continued producing and selling the drug, leading to Welman's lawsuit. Analysts believe the heated fight can be attributed to the drug being included in the national medical insurance in 2005, which offers a promising market. (Click here for more - Chinese language)
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC071308

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel